ATE424111T1 - Formulierungen, die eingeschlossene wirkstoffe enthalten, und ihre verwendung - Google Patents

Formulierungen, die eingeschlossene wirkstoffe enthalten, und ihre verwendung

Info

Publication number
ATE424111T1
ATE424111T1 AT02725430T AT02725430T ATE424111T1 AT E424111 T1 ATE424111 T1 AT E424111T1 AT 02725430 T AT02725430 T AT 02725430T AT 02725430 T AT02725430 T AT 02725430T AT E424111 T1 ATE424111 T1 AT E424111T1
Authority
AT
Austria
Prior art keywords
active ingredients
formulations containing
enclosed active
containing enclosed
formulations
Prior art date
Application number
AT02725430T
Other languages
English (en)
Inventor
Martin Lotz
Alexander Shikhman
San-Bao Hwang
Changyong Hu
Original Assignee
Scripps Research Inst
Optimer Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Optimer Pharmaceuticals filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE424111T1 publication Critical patent/ATE424111T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AT02725430T 2001-03-29 2002-03-29 Formulierungen, die eingeschlossene wirkstoffe enthalten, und ihre verwendung ATE424111T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28035101P 2001-03-29 2001-03-29

Publications (1)

Publication Number Publication Date
ATE424111T1 true ATE424111T1 (de) 2009-03-15

Family

ID=23072710

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02725430T ATE424111T1 (de) 2001-03-29 2002-03-29 Formulierungen, die eingeschlossene wirkstoffe enthalten, und ihre verwendung

Country Status (11)

Country Link
EP (1) EP1379135B1 (de)
JP (1) JP2005500991A (de)
CN (1) CN1499929A (de)
AT (1) ATE424111T1 (de)
AU (1) AU2002255993B2 (de)
CA (1) CA2442146A1 (de)
DE (1) DE60231385D1 (de)
ES (1) ES2322985T3 (de)
MX (1) MXPA03008812A (de)
NZ (1) NZ528544A (de)
WO (1) WO2002078445A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1232256C (zh) * 2003-03-27 2005-12-21 中国人民解放军第三军医大学 N－乙酰氨基葡萄糖在制备治疗自身免疫反应所致的局部损伤或全身症状的药物中的应用
CA2540586A1 (en) * 2003-10-01 2005-04-21 Optimer Pharmaceuticals, Inc. Treatment of a condition in a mammal with administration of aminosugar and uses thereof
US20070082851A1 (en) * 2003-11-24 2007-04-12 Optimer Pharmaceuticals Inc. Treatment of a condition in a mammal with administration of Compounds and Methods of Use
JP5660561B2 (ja) * 2006-09-28 2015-01-28 ハダシット メディカルリサーチサービセス アンド ディベロップメント リミテッド ジョイント部の潤滑に関するグリセロリン脂質の使用
CA2680842C (en) 2007-05-31 2015-11-24 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine or derivatives thereof for use in treating a kidney disorder in a mammal
US8765172B2 (en) * 2007-12-10 2014-07-01 Epitarget As Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids
US20130058998A1 (en) * 2011-09-07 2013-03-07 United States Of America As Represented By The Secretary, Department Of Health And Human Services Encapsulated n-acetylmannosamine or n-acetylneuraminic acid to increase sialylation
WO2019038763A1 (en) * 2017-08-22 2019-02-28 Moebius Medical Ltd. LIPOSOMAL FORMULATION FOR JOINT LUBRICATION
CA3266614A1 (en) 2023-01-19 2024-07-25 Moebius Medical Ltd. LONG-ACTING LIPOSOMAL COMPOSITION FOR THE TREATMENT OF PAIN IN JOINT DISORDERS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1044707B (it) * 1968-10-26 1980-04-21 Rotta Research Lab Procedimento per la preparazione di sali di glucosanina e preparati farmaceutici comprendenti detti sali di glucosamina come agenti attivi
JPS59210013A (ja) * 1983-05-04 1984-11-28 Ajinomoto Co Inc 活性物質含有リポソ−ム
SE8501723L (sv) * 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
DE3602670A1 (de) * 1986-01-29 1987-07-30 Speck Ulrich Verwendung von n-acetylglucosamin zur therapie degenerativer gelenkprozesse und verwandter erkrankungen
WO1989008499A1 (fr) * 1988-03-17 1989-09-21 Nippon Fine Chemical Co., Ltd. Liposome
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
JPH04159216A (ja) * 1990-10-22 1992-06-02 Japan Tobacco Inc グルコサミン誘導体を膜材として含有するリポソーム
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5364845C1 (en) * 1993-03-31 2002-09-10 Nutramax Lab Inc Glusosamine chondroitin and manganese composition for the protection and repair of connective tissue
JP3570561B2 (ja) * 1993-07-27 2004-09-29 テルモ株式会社 血管内皮損傷部位を認識する担体

Also Published As

Publication number Publication date
JP2005500991A (ja) 2005-01-13
ES2322985T3 (es) 2009-07-03
EP1379135A1 (de) 2004-01-14
CA2442146A1 (en) 2002-10-10
EP1379135A4 (de) 2005-08-03
NZ528544A (en) 2006-03-31
AU2002255993B2 (en) 2008-05-01
EP1379135B1 (de) 2009-03-04
MXPA03008812A (es) 2004-10-15
DE60231385D1 (de) 2009-04-16
CN1499929A (zh) 2004-05-26
WO2002078445A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
BR0212921A (pt) Composição farmacêutica com base em fondant
TR200100054T2 (tr) Paroksetin metansülfonat
SV2002000315A (es) Combinaciones de productos activos con propiedades insecticidas y acaricidas ref. lea 34226-sv
DE602004019331D1 (de) Mit malonsäuresalzen stabilisierte terpenoid-duftkomponenten
WO2005000248A3 (en) Compositions and methods for skin conditioning
ATE433750T1 (de) Zusammensetzungen, die combretastatin und krebsbekämpfendes mittel enthalten
DE50007791D1 (de) Parfümkomposition mit duftsequenz
ATE256392T1 (de) Verwendung von polyaminosäurederivate als konservierungsmittel
WO2003066597A3 (en) Guanidino compounds
ATE424111T1 (de) Formulierungen, die eingeschlossene wirkstoffe enthalten, und ihre verwendung
DE60116359D1 (de) Kahalalid f formulierung
ES2180319T3 (es) Utilizacion de derivados de metilenbisoxazolidina y composiciones de los mismos.
AU2525301A (en) Genus leontopodium plant extract and compositions containing same
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
AR038560A1 (es) Una composicion antitranspirante/ desodorante
DE60120689D1 (de) Verwendung einer antioxidativen zusammensetzung enthaltend einen extrakt aus mozuku-algen
AU2001293925A1 (en) Method for obtaining an active principle with immediate skin-tightening effect and resulting active principle
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
AU2003236764A1 (en) Fragrance composition
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
ES2191426T3 (es) Composiciones estables que comprenden levosimendano y acido alginico.
PT1358159E (pt) Tartrato e fosfato de 3,4 diaminopiridina, as suas composições farmacêuticas e as suas utilizações
ITRM20020119A0 (it) Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
AR006034A1 (es) Una composicion antitranspirante, un sistema antitranspirante que la comprende y la utilizacion de un emoliente en la preparacion de la misma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties